Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center
暂无分享,去创建一个
[1] M. Kanehisa,et al. KEGG for taxonomy-based analysis of pathways and genomes , 2022, Nucleic Acids Res..
[2] Shaozhang Zhou,et al. Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy , 2021, Frontiers in Oncology.
[3] Minoru Kanehisa,et al. Toward understanding the origin and evolution of cellular organisms , 2019, Protein science : a publication of the Protein Society.
[4] C. Liang,et al. The Hypermethylation of Foxp3 Promoter Impairs the Function of Treg Cells in EAP , 2019, Inflammation.
[5] R. Lothe,et al. Combination therapies with HSP90 inhibitors against colorectal cancer. , 2019, Biochimica et biophysica acta. Reviews on cancer.
[6] K. Richter,et al. Regulation of the Hsp90 system. , 2018, Biochimica et biophysica acta. Molecular cell research.
[7] A. Jemal,et al. Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[8] M. Pike,et al. Timing of births and oral contraceptive use influences ovarian cancer risk , 2017, International journal of cancer.
[9] Thomas A. Sellers,et al. Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.
[10] C. Prodromou. Mechanisms of Hsp90 regulation , 2016, The Biochemical journal.
[11] Yukihide Iwamoto,et al. Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma , 2015, BMC Cancer.
[12] Setia Pramana,et al. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival , 2015, Bioinform..
[13] Feng-Hou Gao,et al. Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells , 2015, PloS one.
[14] Qian Liu,et al. Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients. , 2015, International journal of clinical and experimental pathology.
[15] Ji-Eun Lee,et al. Mitochondrial Hsp90s suppress calcium-mediated stress signals propagating from mitochondria to the ER in cancer cells , 2014, Molecular Cancer.
[16] F. Ajili,et al. Prognostic Significance of Heat Shock Protein 90 in Non Muscle Invasive Bladder Cancer Treated by BCG Immunotherapy , 2014 .
[17] M. Bianchini,et al. CAMKIIγ, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease , 2014, Leukemia & lymphoma.
[18] J. Buchner,et al. Structure, Function and Regulation of the Hsp90 Machinery , 2013, Biomedical journal.
[19] S. Soga,et al. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. , 2012, Current pharmaceutical design.
[20] M. Hance,et al. Secreted Hsp90 Is a Novel Regulator of the Epithelial to Mesenchymal Transition (EMT) in Prostate Cancer* , 2012, The Journal of Biological Chemistry.
[21] Rong Biaoxue,et al. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients , 2012, Journal of experimental & clinical cancer research : CR.
[22] Jeffrey T. Chang,et al. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer , 2012, Breast Cancer Research.
[23] Walid A Houry,et al. The role of Hsp90 in protein complex assembly. , 2012, Biochimica et biophysica acta.
[24] Renaud Seigneuric,et al. Heat Shock Proteins as Danger Signals for Cancer Detection , 2011, Front. Oncol..
[25] Kenneth P. Nephew,et al. Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.
[26] Z. Hořejší,et al. CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability. , 2010, Molecular cell.
[27] N. Pavletich,et al. Tel2 structure and function in the Hsp90-dependent maturation of mTOR and ATR complexes. , 2010, Genes & development.
[28] M. Fares,et al. The Effect of Chaperonin Buffering on Protein Evolution , 2010, Genome biology and evolution.
[29] Doo Jae Lee,et al. Cytosolic Hsp60 Is Involved in the NF-κB-Dependent Survival of Cancer Cells via IKK Regulation , 2010, PloS one.
[30] Sung-Won Kim,et al. Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers , 2010, Breast Cancer Research.
[31] Z. Prohászka,et al. Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis , 2010, Cell Stress and Chaperones.
[32] L. Frati,et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer , 2010, Tumor Biology.
[33] K. West,et al. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. , 2009, Current topics in medicinal chemistry.
[34] G. Coukos,et al. Immunotherapy opportunities in ovarian cancer , 2008, Expert review of anticancer therapy.
[35] L. Neckers,et al. Extracellular heat shock protein 90: A role for a molecular chaperone in cell motility and cancer metastasis , 2007, Cancer science.
[36] K. Anderson,et al. Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib * , 2006, British journal of haematology.
[37] Christopher P Crum,et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.
[38] Laurence H Pearl,et al. Hsp90 and Cdc37 -- a chaperone cancer conspiracy. , 2005, Current opinion in genetics & development.
[39] W. Stolz,et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases , 2004, Experimental dermatology.
[40] I. Yahara. The role of HSP90 in evolution , 1999, Genes to cells : devoted to molecular & cellular mechanisms.
[41] Z. Naito,et al. Expression of hsp90 and cyclin D1 in human breast cancer. , 1999, Cancer letters.
[42] L. Pearl,et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.
[43] S. Lindquist,et al. Hsp90 as a capacitor for morphological evolution , 1998, Nature.
[44] C. Kirchhoff. Molecular characterization of epididymal proteins. , 1998, Reviews of reproduction.
[45] W. Pratt. The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[46] J. Johnson,et al. A novel chaperone complex for steroid receptors involving heat shock proteins, immunophilins, and p23. , 1994, The Journal of biological chemistry.
[47] B. Karlan,et al. OVARIAN CANCER , 2016, Nature Reviews Disease Primers.
[48] S. Lindquist,et al. Protein folding sculpting evolutionary change. , 2009, Cold Spring Harbor symposia on quantitative biology.
[49] W. Pratt,et al. Chaperoning of glucocorticoid receptors. , 2006, Handbook of experimental pharmacology.
[50] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[51] Susumu Goto,et al. KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..